Acepodia, Inc. Stock

6976

KYG0073G1091

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 2026-10-01			5-day change	1st Jan Change
12.80 ^TWD	-0.39%		-1.54%	-16.61%

09-04	Acepodia Receives FDA Clearance for Ind Application for ACE723, A Novel Dual-Payload Antibody-Drug Conjugate	CI
08-13	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Acepodia Inc is engaged in the research and development of new anti-cancer drugs. The Company uses antibody-cell conjugation (ACC) and immune cells. The products include Gamma delta 2T cell platform including ACE1831 (ACE-gdT-CD20) an antibody linked to specific target CD20 for treatment of lymphoma, ACE2016 (ACE-gdT-EGFR) an antibody linked to specific target EGFR , the target treatment of EGFR+ solid tumors, such as lung cancer, ACE1708 (ACE-gdT-PDL1) an antibody linked to the specific target PDL1 antibody, the target treatment of solid tumors; off-the-shelf natural killer (oNK) cell platform including ACE1702 (ACE-oNK-HER2) linked to a specific target HER2 antibody, targeting treatment of HER2+ solid tumors, such as breast cancer. The technologies include antibody cell linking technology, Gamma delta 2T cell screening, culture and amplification technology, oNK cell culture and amplification technology, Acepodia series of new cell drug preparations freezing and thawing technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-01	NT$12.80	-0.39%	262,810
26-09-30	NT$12.85	+0.39%	453,315
26-09-29	NT$12.80	-0.78%	552,905
26-09-24	NT$12.90	-0.77%	334,306
26-09-23	NT$13.00	+3.59%	421,276

End-of-day quote Taipei Exchange

More quotes

Stock Market
Stocks
6976 Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	7.46B 234M 208M 194M 177M 332M 22.53B 338M 2.35B 909M 11.49B 878M 859M 36.98B	P/E 2024	-20x	P/E 2025	-11.8x
Enterprise Value	3.92B 123M 109M 102M 93.04M 175M 11.84B 178M 1.23B 478M 6.03B 461M 451M 19.43B	EV / Sales 2024	9,735,924,522x	EV / Sales 2025	29,160,315,200x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

09-04	Acepodia Receives FDA Clearance for Ind Application for ACE723, A Novel Dual-Payload Antibody-Drug Conjugate	CI
08-13	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-12	Acepodia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-09	Biocytogen Pharmaceuticals Co., Ltd. and AcePodia Expand Collaboration Through Option-Based Evaluation Framework for First-In-Class Bispecific and Dual-Payload ADCs	CI
25-08-13	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-05-28	Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development	RE
25-05-28	AcePodia, Inc. Provides Update on Collaboration Under the Pfizer Ignite Program	CI
25-05-28	Acepodia, Inc. Announces CFO Changes, Effective from May 28, 2025	CI
25-05-28	Taiyo Yuden Co., Ltd. Announces Executive Changes, Effective from May 28, 2025	CI
25-03-19	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-17	AcePodia Biotech, Inc. Announces Clearance of the IND by the Taiwan Food and Drug Administration for Investigational Product ACE2016	CI
25-01-07	Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors	CI

1 day	-0.39%
1 week	-1.54%
Current month	-0.39%
1 month	+7.11%
3 months	-3.76%
6 months	+5.79%
Current year	-16.61%

1 week	12.65	13.4
1 month	11.65	13.9
Current year	10.85	15.75
1 year	10.85	17.9
3 years	10.85	40.4
5 years	10.85	65
10 years	10.85	65

Manager	Title	Age	Since
Sonny Hsiao CEO	Chief Executive Officer	-	2017-02-14
Yan Ta Lai DFI	Director of Finance/CFO	-	2017-03-31
Lapyuen Lam CTO	Chief Tech/Sci/R&D Officer	68	2022-03-31

Acepodia, Inc. Stock

Stocks

6976

KYG0073G1091

Biotechnology & Medical Research

Valuation: Acepodia, Inc.

Chart: Acepodia, Inc.

Latest news: Acepodia, Inc.

Press Releases: Acepodia, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Acepodia, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Patrick Yang CHM	Chairman	78	2017-02-14
Sonny Hsiao BRD	Director/Board Member	-	2017-02-14
Samuel Chen BRD	Director/Board Member	75	2021-10-13

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACEPODIA, INC.	-0.39%	-1.54%	-28.09%	-66.49%	235M
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.61%	+0.69%	+36.36%	+82.72%	60.14B
LONZA GROUP AG	-2.54%	-0.21%	+6.34%	+31.72%	48.15B
IQVIA HOLDINGS INC.	-3.02%	-2.67%	+37.26%	+32.51%	44.25B
REVOLUTION MEDICINES, INC.	+0.31%	+7.94%	+340.88%	+643.82%	43.99B
BEONE MEDICINES AG	-1.96%	-1.71%	+5.30%	+99.46%	41.61B
CELLTRION, INC.	+3.32%	+3.49%	+11.18%	+51.23%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-4.86%	-8.24%	-24.60%	+330.06%	24.93B
Average	-0.08%	+1.62%	+47.08%	+132.20%	39.7B
Weighted average by Cap.	+0.17%	+1.83%	+60.01%	+145.65%

	2024	2025
Net sales	0.43 0.01 0.01 0.01 0.01 0.02 1.29 0.02 0.13 0.05 0.66 0.05 0.05 2.12	0.18 0.01 0.01 0 0 0.01 0.56 0.01 0.06 0.02 0.28 0.02 0.02 0.92
Net income	-497M -15.58M -13.84M -12.93M -11.79M -22.12M -1.5B -22.5M -156M -60.56M -765M -58.48M -57.21M -2.46B	-754M -23.66M -21.02M -19.63M -17.91M -33.59M -2.28B -34.17M -237M -91.97M -1.16B -88.81M -86.88M -3.74B
Net Debt	-5.82B -182M -162M -151M -138M -259M -17.58B -264M -1.83B -709M -8.96B -685M -670M -28.85B	-3.54B -111M -98.69M -92.17M -84.07M -158M -10.7B -160M -1.11B -432M -5.45B -417M -408M -17.55B